Journal of Biological Chemistry · 2008 · 65 citations · 44 references
Life SciencesBiochemistryMolecular BiologyStructural BiochemistryStructural BiologyStructure-activity RelationshipsBone Morphogenetic Protein SignalingLigand BindingReceptor-ligand InteractionsStructural DomainsStructure-function RelationshipsAntagonist ActivityAntagonist InteractionsDomain-domain InteractionsLigand SelectivityReceptor-ligand SpecificityReceptor-ligand Structural BiologyStructural Basis Of SpecificityX-ray Structure Determination
Transforming growth factor β family ligands are neutralized by a number of structurally divergent antagonists. Follistatin-type antagonists, which include splice variants of follistatin (FS288 and FS315) and follistatin-like 3 (FSTL3), have high affinity for activin A but differ in their affinity for other ligands, particularly bone morphogenetic proteins. To understand the structural basis for ligand specificity within FS-type antagonists, we determined the x-ray structure of activin A in complex with FSTL3 to a resolution of 2.5 Å. Similar to the previously resolved FS·activin A structures, the ligand is encircled by two antagonist molecules blocking all ligand receptor-binding sites. Recently, the significance of the FS N-terminal domain interaction at the ligand type I receptor site has been questioned; however, our data show that for FSTL3, the N-terminal domain forms a more intimate contact with activin A, implying that this interaction is stronger than that for FS. Furthermore, binding studies revealed that replacing the FSTL3 N-terminal domain with the corresponding FS domain considerably lowers activin A affinity. Therefore, both structural and biochemical evidence support a significant interaction of the N-terminal domain of FSTL3 with activin A. In addition, structural comparisons with bone morphogenetic proteins suggest that the interface where the N-terminal domain binds may be the key site for determining FS-type antagonist specificity. Transforming growth factor β family ligands are neutralized by a number of structurally divergent antagonists. Follistatin-type antagonists, which include splice variants of follistatin (FS288 and FS315) and follistatin-like 3 (FSTL3), have high affinity for activin A but differ in their affinity for other ligands, particularly bone morphogenetic proteins. To understand the structural basis for ligand specificity within FS-type antagonists, we determined the x-ray structure of activin A in complex with FSTL3 to a resolution of 2.5 Å. Similar to the previously resolved FS·activin A structures, the ligand is encircled by two antagonist molecules blocking all ligand receptor-binding sites. Recently, the significance of the FS N-terminal domain interaction at the ligand type I receptor site has been questioned; however, our data show that for FSTL3, the N-terminal domain forms a more intimate contact with activin A, implying that this interaction is stronger than that for FS. Furthermore, binding studies revealed that replacing the FSTL3 N-terminal domain with the corresponding FS domain considerably lowers activin A affinity. Therefore, both structural and biochemical evidence support a significant interaction of the N-terminal domain of FSTL3 with activin A. In addition, structural comparisons with bone morphogenetic proteins suggest that the interface where the N-terminal domain binds may be the key site for determining FS-type antagonist specificity. The transforming growth factor (TGF) 2The abbreviations used are: TGF, transforming growth factor; FS, follistatin; FSTL3, follistatin-like 3; BMP, bone morphogenetic protein; FSD, follistatin domain; ND, N-terminal domain; BRIA, BMP type IA receptor; COM, center of mass. β superfamily of ligands controls a wide array of processes that govern stem cell fate, embryonic development, organ and tissue homeostasis, reproduction, response to injury, and immune system function. Thirty-three ligands can be subdivided into three branches: TGFβ, activin/inhibin, and bone morphogenetic protein (BMP) (1Shi Y. Massague J. Cell. 2003; 113: 685-700Abstract Full Text Full Text PDF PubMed Scopus (4836) Google Scholar). Each ligand is comprised of a disulfide-linked homo- or heterodimer and signals by engaging a pair of type II and type I serine-threonine kinase receptors. Tight control of ligand signaling occurs in the extracellular space, where a number of structurally diverse protein antagonists attenuate or completely inhibit signaling by binding and sequestering ligands. Antagonists include the follistatin-types, noggin, chordin, DAN/Cerberus, gremlin, decorin, and others. Antagonists restrict ligand activity to certain physiological environments and will often selectively inhibit ligands from one of the three branches. Antagonists bind multiple ligands with varying affinities, and for the most part, the structural basis for this specificity remains unresolved (2Shimmi O. Umulis D. Othmer H. O'Connor M.B. Cell. 2005; 120: 873-886Abstract Full Text Full Text PDF PubMed Scopus (240) Google Scholar, 3Amthor H. Christ B. Rashid-Doubell F. Kemp C.F. Lang E. Patel K. Dev. Biol. 2002; 243: 115-127Crossref PubMed Scopus (103) Google Scholar). Follistatin-type (FS-type) antagonists, which include the well studied splice variants of follistatin (FS), FS288 and FS315, are potent regulators of activin A signaling (4Nakamura T. Takio K. Eto Y. Shibai H. Titani K. Sugino H. Science. 1990; 247: 836-838Crossref PubMed Scopus (793) Google Scholar, 5Inouye S. Guo Y. DePaolo L. Shimonaka M. Ling N. Shimasaki S. Endocrinology. 1991; 129: 815-822Crossref PubMed Scopus (147) Google Scholar, 6Michel U. Farnworth P. Findlay J.K. Mol. Cell Endocrinol. 1993; 91: 1-11Crossref PubMed Scopus (136) Google Scholar, 7Sugino K. Kurosawa N. Nakamura T. Takio K. Shimasaki S. Ling N. Titani K. Sugino H. J. Biol. Chem. 1993; 268: 15579-15587Abstract Full Text PDF PubMed Google Scholar). Also included is a related protein, follistatin-like 3 (FSTL3/FLRG/FSRP), that was originally identified in B-cell leukemia (8Hayette S. Gadoux M. Martel S. Bertrand S. Tigaud I. Magaud J.P. Rimokh R. Oncogene. 1998; 16: 2949-2954Crossref PubMed Scopus (102) Google Scholar). FSTL3 is similar to FS in that it is distributed among many tissues and cell types (9Tsuchida K. Arai K.Y. Kuramoto Y. Yamakawa N. Hasegawa Y. Sugino H. J. Biol. Chem. 2000; 275: 40788-40796Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar, 10Schneyer A. Tortoriello D. Sidis Y. Keutmann H. Matsuzaki T. Holmes W. Mol. Cell Endocrinol. 2001; 180: 33-38Crossref PubMed Scopus (65) Google Scholar, 11Tsuchida K. Nakatani M. Matsuzaki T. Yamakawa N. Liu Z. Bao Y. Arai K.Y. Murakami T. Takehara Y. Kurisaki A. Sugino H. Mol. Cell Endocrinol. 2004; 225: 1-8Crossref PubMed Scopus (40) Google Scholar). Mice deficient in each form exhibit drastically different phenotypes. FS-deficient mice show retarded growth and death within hours of birth (12Matzuk M.M. Lu N. Vogel H. Sellheyer K. Roop D.R. Bradley A. Nature. 1995; 374: 360-363Crossref PubMed Scopus (512) Google Scholar), whereas FSTL3-deficient mice are viable and normal-sized but exhibit metabolic phenotypes characterized by changes in glucose and fat homeostasis (13Mukherjee A. Sidis Y. Mahan A. Raher M.J. Xia Y. Rosen E.D. Bloch K.D. Thomas M.K. Schneyer A.L. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 1348-1353Crossref PubMed Scopus (126) Google Scholar). Although both FSTL3 and FS bind activin A with high affinity (Kd ∼ 30 pm), they exhibit affinity differences with other ligands. FS exhibits broad ligand specificity, interacting at high affinity with numerous ligands including activin B, myostatin, and growth and differentiation factor 11 and at low affinity with several BMPs (11Tsuchida K. Nakatani M. Matsuzaki T. Yamakawa N. Liu Z. Bao Y. Arai K.Y. Murakami T. Takehara Y. Kurisaki A. Sugino H. Mol. Cell Endocrinol. 2004; 225: 1-8Crossref PubMed Scopus (40) Google Scholar, 14Iemura S. Yamamoto T.S. Takagi C. Uchiyama H. Natsume T. Shimasaki S. Sugino H. Ueno N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 9337-9342Crossref PubMed Scopus (380) Google Scholar, 15Welt C. Sidis Y. Keutmann H. Schneyer A. Exp. Biol. Med. (Maywood). 2002; 227: 724-752Crossref PubMed Scopus (282) Google Scholar, 16Lin S.Y. Morrison J.R. Phillips D.J. de Kretser D.M. Reproduction. 2003; 126: 133-148Crossref PubMed Scopus (94) Google Scholar, 17Sidis Y. Mukherjee A. Keutmann H. Delbaere A. Sadatsuki M. Schneyer A. Endocrinology. 2006; 147: 3586-3597Crossref PubMed Scopus (171) Google Scholar). Recently, however, it was determined that FSTL3 is more limited than FS in the number of ligands it antagonizes, and it lacks interaction with BMPs, specifically BMPs 2, 4, 6, and 7 (17Sidis Y. Mukherjee A. Keutmann H. Delbaere A. Sadatsuki M. Schneyer A. Endocrinology. 2006; 147: 3586-3597Crossref PubMed Scopus (171) Google Scholar). Differences in the domain structures of FSTL3 and FS likely provide a basis for ligand specificity. All of the follistatin antagonists possess an N-terminal domain followed by two or three follistatin domains (FSD) (Fig. 1). Despite similar architecture, there are significant differences between FSTL3 and FS288/FS315: (i) FS288/FS315 both have three FSDs, whereas FSTL3 contains only two; (ii) the sequences of FSD1 and are well between FS and FSTL3, but the N-terminal domains are more divergent and FSTL3 lacks a cell in FSD1 of K. Kurosawa N. Nakamura T. Takio K. Shimasaki S. Ling N. Titani K. Sugino H. J. Biol. Chem. 1993; 268: 15579-15587Abstract Full Text PDF PubMed Google Scholar), which it the most form Y. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar, A.L. Sidis Y. J. Endocrinol. 2004; PubMed Scopus Google Scholar). The of each FS domain to ligand binding and has been with to the N-terminal In one or of the N-terminal domain of FS both binding to activin A and of activin A activity Y. Schneyer A.L. Keutmann J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google Scholar). other studies have the of the N-terminal domain to a FS only FSD1 and was to form a complex with activin A and was to of S. M. J. 2006; PubMed Scopus (126) Google Scholar). the for this form was or than for FS. Similar that activin A binding be the two of FSTL3 (9Tsuchida K. Arai K.Y. Kuramoto Y. Yamakawa N. Hasegawa Y. Sugino H. J. Biol. Chem. 2000; 275: 40788-40796Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar, K.Y. K. C. Sugino H. K. T. 2006; PubMed Scopus Google Scholar). Furthermore, of activin A the N-terminal domain interface however, certain activin A to D.M. Endocrinology. 2006; 147: PubMed Scopus Google Scholar). To understand the structural that for the differences in ligand specificity between FS and FSTL3 and the of the N-terminal domain in we have the x-ray structure at 2.5 of FSTL3 in complex with activin A. The A structure that a binding for FS-type antagonists where FSD1 and the type II receptor and the N-terminal domain at the type I receptor with the previously determined FS·activin A structures T.S. Dev. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar, Shimasaki S. T.S. J. Biol. Chem. 2007; Full Text Full Text PDF PubMed Scopus Google that significant differences within the N-terminal to a structural basis for ligand specificity. to our structural and of FSTL3 and FSTL3 and activin A each into the previously for FS Y. Schneyer A.L. Keutmann J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google Scholar, Schneyer A.L. Sidis Y. Mol. Endocrinol. 2004; PubMed Scopus Google and in the system The was for activin A and include the was was a affinity and with a activin A and FSTL3 between and The complex was with to the and a protein in The protein was at an with a complex of FSTL3 and activin A. A complex was to and in a with a well and to within The at the The data and to 2.5 resolution Z. W. PubMed Scopus Google Scholar). The of two in the resolved with the Biol. 2005; PubMed Scopus Google Scholar), and the A complex with from the T.S. Dev. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). The P. J. M. T. Biol. 1998; PubMed Scopus Google and P. K. Biol. 2004; PubMed Scopus Google with of with Biol. PubMed Scopus Google Scholar). of each was by that identified by the J. Biol. 2006; PubMed Scopus Google Scholar, J. J. 2006; Scopus Google Scholar). and the x-ray data with and and Biol. 2001; PubMed Scopus Google Scholar). with with The two of A a of Å. The for activin A are N-terminal the and in the from FSTL3 are and and are in and an of the of the complex interface is in and structure have been in the with the of and with the E. K. J. Mol. Biol. 2007; PubMed Scopus Google data and at cell β factor from all A A molecules in all activin A in a N-terminal of FSTL3 with the of FS288 in the Schneyer A.L. Sidis Y. Mol. Endocrinol. 2004; PubMed Scopus Google and A the FS domain into the of the to The proteins in and by affinity was by a Y. Schneyer A.L. Keutmann J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google Scholar). of to activin A was determined by Y. Schneyer A.L. Keutmann J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google Scholar). by of of activin A binding by and of x-ray structure of A has been determined to 2.5 and an of the complex is in The previously determined structure of A is for in Similar to FS288 and FS315, two molecules of FSTL3, each a completely the activin A the two FSTL3 molecules of the activin A or a of which is similar to FS288 with FS, FSTL3 molecules contact activin A at two with both type I and type II receptor-binding (Fig. interface is the N-terminal domain of FSTL3 at the activin A FSTL3 with the of the one activin A and the or of the activin A I The other interface is by FSD1 and which the ligand or and the of one activin A II the two FS-type contact will be to type I and type corresponding to the receptor-binding that they In both FS·activin A structures, the N-terminal domain of one FS with of the other FS, to (Fig. FSTL3 have a follistatin this interaction is In there are between the two FSTL3 molecules the The significance of the N-terminal domain interaction with activin A Y. Schneyer A.L. Keutmann J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google has been by evidence S. M. J. 2006; PubMed Scopus (126) Google Scholar, D.M. Endocrinology. 2006; 147: PubMed Scopus Google Scholar). the structure of A (Fig. 2, a and in the of the N-terminal domain is at the type I of A to the A BMP ligands, which exhibit in the of each structures of activin A, and in have significant at the in that from or to S. M. J. 2006; PubMed Scopus (126) Google Scholar, T.S. Dev. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar, J. W. S. Mol. Cell. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, T.S. J. 2003; PubMed Scopus Google The of the activin A is a of numerous and in the the at the to the is in activin A structures that more S. M. J. 2006; PubMed Scopus (126) Google Scholar, J. W. S. Mol. Cell. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, T.S. J. 2003; PubMed Scopus Google Scholar). In all with FS-type antagonists, including FSTL3, the activin A is is likely a of the N-terminal domain binding in the type I II and to the FS·activin A structures, one of the two A is where the type II bind FSD1 and a of the of activin A. that with activin A at the type II interface are well between FSTL3 and FS FSTL3 and FS bind activin A by type II and this of activin A with the activin type II receptor which has been to and J. W. S. Mol. Cell. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, T.S. J. 2003; PubMed Scopus Google In to most of the type II receptor the of activin A form with and of activin A, which are in the receptor this a in FS and in the two activin A at the ligand a with and and a interaction with of activin A. of in a of FS considerably activin A affinity S. M. J. 2006; PubMed Scopus (126) Google Scholar). the other of the the type II with activin A that contact FSTL3 or FS and differences in activin A which are both and antagonists, may be for that selectively antagonist or receptor I with the FS·activin A structures, the N-terminal domain of FSTL3 binds at the activin A or the type I receptor site (Fig. 2, a and interface is by the of one and to in 3 and and the and of the other and to the N-terminal domains of both FSTL3 and FS bind in a similar and a of activin A and their in binding at the type II we significant structural differences between the FSTL3 and FS N-terminal The two N-terminal domains have a of which the in (Fig. and is than differences in FSD1 and L. J. 2000; 16: PubMed Scopus Google Scholar). differences in each N-terminal domain with activin A. FSTL3 to a with whereas FS has with the of (Fig. The in of the two have been the ligand in FSTL3 to a with the whereas FS more with the of of FSTL3 and FS N-terminal domain with activin A. a and the N-terminal domain of FSTL3 is more than that of FS to activin A The activin A is to FSTL3, whereas in FS it forms the are significant structural differences in the the of only activin A in both which the of the each N-terminal domain to activin A. The N-terminal domain of FSTL3, including the is to activin A by and The from the center of of activin A to the of each N-terminal domain or the of each and FS The where FSTL3 with the of activin A from the FS of only the N-terminal The FSTL3 domain is more with to the The between the was from the of FSTL3 to the of FS All of the with the S. A. PubMed Google Scholar). In and the structure is from and differences in the N-terminal with the two and of activin A. A significant in the of is in the two this of FSTL3 to between and of activin A in the N-terminal domain in FSTL3 and in 4, a and a of the interface with the activin A Differences in the of FSTL3 to to the activin A the of (Fig. 4, a and In this in FSTL3 more than the corresponding FS activin A of each complex that the N-terminal domain of FSTL3, including is to the activin A interface (Fig. the N-terminal domain of FSTL3 is more than that of FS, and this to activin A with the of activin (Fig. 4, and In FS, a is between the N-terminal domain and the in in the of activin A into this and the the more N-terminal domain of FSTL3 lacks this in FSTL3 have an interaction that a of the in activin A. of FSTL3 activin A in the FS structure that activin A the a with FSTL3 in The structural in of the N-terminal domain may from in the of the N-terminal domain for FSTL3 and for in FS has a that into the to a more whereas the in FSTL3 from the it to (Fig. 4, a and In the in FSTL3 forms at one contact with activin A in FS A of the two domains in that FSTL3 is more than FS. The N-terminal domain of FSTL3 is by the the center of the domain than the corresponding FS a I for a similar of is by both N-terminal domains of FSTL3 and FS, FSTL3 more with the of activin A, implying that interaction is stronger and more A significant of the FSTL3 N-terminal domain interaction occurs at the more of whereas the N-terminal domain of FS with in the of (Fig. and the center of the is a pair of and that are all family ligands. The and their corresponding interaction with antagonist are different in the two structures (Fig. 4, and FSTL3 a that a between the the N-terminal domain into the between the the N-terminal domain to activin A. the of at this the other in the FS and are in a similar to structures of activin A or in complex with S. M. J. 2006; PubMed Scopus (126) Google Scholar, T.S. Dev. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar, J. W. S. Mol. Cell. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, T.S. J. 2003; PubMed Scopus Google Scholar). the N-terminal domain activin A. suggest a stronger interaction between activin A and the N-terminal domain of FSTL3 FS. The to activin A a interaction between of FSTL3 and of activin A, and interaction between of FSTL3 and of activin A. the from the N-terminal domain and interaction with may the of this and to the of the N-terminal are for in FS. a for the FSTL3 N-terminal structure of FSTL3 in complex with activin A has that the interaction between the N-terminal domain and the type I interface is stronger than that for the N-terminal domain of FS. To our structural we the N-terminal domain of FSTL3 with FS activin A binding with FS that the N-terminal domains are the follistatin domain to the activin A The was that contact the N-terminal domain the FS and it in the type I receptor in the A structure T.S. Dev. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). the follistatin domain is to activin A binding is that the the of the N-terminal domain of FS to bind activin A. from FS, where of only a in activin A binding Schneyer A.L. Sidis Y. Mol. Endocrinol. 2004; PubMed Scopus Google Scholar). with the structural we that the N-terminal domain of FSTL3 more with activin A, the for a follistatin activin A binding activity of domain in binding activin A in Y. Schneyer A.L. Keutmann J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google in a I x-ray structures have that type I receptor binding occurs at or the interface of the ligand S. Proc. Natl. Acad. Sci. U. S. A. 2006; PubMed Scopus Google Scholar, T. W. M.K. Biol. 2000; PubMed Scopus Google Scholar, D. A. J. S. A. U. W. Biol. 2007; PubMed Scopus Google Scholar, J. P. C. J.P. Mol. Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). resolution of the FS we identified a between type I receptor binding and N-terminal domain structure this to include the N-terminal domain of Despite different there are structural between the receptor and the N-terminal domains that a similar for ligand both a domain of similar that of with a at the is in to the antagonist noggin, which an and a domain to at the type I interface J. J. E. J. W. M. S. Nature. 2002; PubMed Scopus Google Scholar). The N-terminal domains and the receptor a the and that into the ligand (Fig. Despite both FSTL3 and FS this the two antagonists a with different (Fig. In FSTL3, is at the of the N-terminal domain and is to into the than in a in the and an is for in FS (Fig. The of may the N-terminal domain to activin A. among the three is in a that the (Fig. are the from the antagonist is to the from the of family ligands by of binding extracellular antagonists is a of Antagonists into structurally that bind certain ligands with different Y. J. W. J. Biol. Chem. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar). The structure of FSTL3 in complex with activin A and with previously determined FS structures provide a system to the and differences in specificity and affinity within a of structurally related antagonists. will center the significance of the N-terminal domain and structural differences between FSTL3 and FS. The of the N-terminal in from the FS·activin A structure was that in to the type II receptor FS the type I receptor site of N-terminal domain T.S. Dev. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). is resolution of the structure of the A In the interaction of the FSTL3 N-terminal domain with activin A In the FS·activin A the N-terminal domain with of an FS which may the N-terminal domain at the type I interaction is in the A structure there is the N-terminal domain of FSTL3 binds activin A. To with the of activin A and for the the N-terminal domain of FSTL3 a more In of FSTL3 is by the two in all family ligands. is by our domain that that the N-terminal domain of FS the N-terminal domain of FSTL3 for The is that the N-terminal domains in both FS and FSTL3 form a but significant interaction at the ligand for basis for FS and FSTL3 both bind activin A but have or affinity for BMP ligands has been resolved S. Yamamoto T.S. Takagi C. Uchiyama H. Natsume T. Shimasaki S. Sugino H. Ueno N. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 9337-9342Crossref PubMed Scopus (380) Google Scholar, 17Sidis Y. Mukherjee A. Keutmann H. Delbaere A. Sadatsuki M. Schneyer A. Endocrinology. 2006; 147: 3586-3597Crossref PubMed Scopus (171) Google Scholar, C. Kemp C.F. Reproduction. 2004; PubMed Scopus Google Scholar). To this we BMPs and 7 activin A in the structures of the FS288 and FSTL3 In both the N-terminal domains with the of the BMP ligands (Fig. a and The (Fig. a and more for the N-terminal domain of FSTL3 than FS. In to the of activin A, the of the BMP ligands in the that N-terminal domain binding be S. Proc. Natl. Acad. Sci. U. S. A. 2006; PubMed Scopus Google Scholar, T. W. M.K. Biol. 2000; PubMed Scopus Google Scholar, J. J. E. J. W. M. S. Nature. 2002; PubMed Scopus Google Scholar, J. J. P. E. W. W. S. Mol. Cell. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar, S. J. W. Mol. Biol. 2004; PubMed Scopus Google Scholar). Therefore, we a where a significant in affinity for BMPs is a of N-terminal domain binding (Fig. The low affinity of FS for BMPs may be a of the interaction for FSTL3 or may from structural differences in the N-terminal In support of this ligands type I structural in the T. W. M.K. Biol. 2000; PubMed Scopus Google Scholar, J. A. W. J. Mol. Biol. 2005; PubMed Scopus Google Scholar, U. W. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). is with our that N-terminal in several type I receptors. Furthermore, activin A can be to a ligand by the and including the J. A. W. J. Mol. Biol. 2005; PubMed Scopus Google Scholar, U. W. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). Therefore, we FS-type antagonists to the type I interface for ligand specificity, type I receptors. The physiological basis for multiple FS-type molecules with varying for has been the that specificity the of the FS-type antagonist is a broad antagonist into the likely have multiple x-ray structure of A complex and with the previously determined FS·activin A structures an for this ligand The our structural studies will in the and of antagonists for ligand specificity is an factor in with
44
Inference of Macromolecular Assemblies from Crystalline State
Evgeny Krissinel, Kim Henrick · Journal of Molecular Biology · 2007 · 10.4K citations · Full text